Key result
RV-arterial uncoupling linked to ~121% higher risk of major events.
Why the study?
CAD contributes to the pathophysiological characteristics of HFpEF, but the prognostic value of RV-arterial uncoupling in acute HFpEF patients with CAD required evaluation.
Does right ventricular-arterial uncoupling predict adverse outcomes in acute HFpEF patients with coronary artery disease?
Cohort (n=250)
Does right ventricular-arterial uncoupling predict adverse outcomes in acute HFpEF patients with coronary artery disease?
Hazard Ratio: 2.21 (95% CI 1.44–3.39)
p-value: p=<0.001
Right ventricular-arterial uncoupling, as measured by TAPSE/PASP ≤0.43, is an independent predictor of adverse outcomes in patients with acute HFpEF and coronary artery disease.
May aid prognostication; hypothesis-generating for targeted therapies, requiring prospective validation.
BACKGROUND: Right ventricular (RV)-arterial uncoupling is a powerful independent predictor of prognosis in heart failure with preserved ejection fraction (HFpEF). Coronary artery disease (CAD) can contribute to the pathophysiological characteristics of HFpEF. This study aimed to evaluate the prognostic value of RV-arterial uncoupling in acute HFpEF patients with CAD. METHODS: This prospective study included 250 consecutive acute HFpEF patients with CAD. Patients were divided into RV-arterial uncoupling and coupling groups by the optimal cutoff value, based on a receiver operating characteristic curve of tricuspid annular plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP). The primary endpoint was a composite of all-cause death, recurrent ischemic events, and HF hospitalizations. RESULTS: TAPSE/PASP ≤0.43 provided good accuracy in identifying patients with RV-arterial uncoupling (area under the curve, 0.731; sensitivity, 61.4%; and specificity, 76.6%). Of the 250 patients, 150 and 100 patients could be grouped into the RV-arterial coupling (TAPSE/PASP >0.43) and uncoupling (TAPSE/PASP ≤0.43) groups, respectively. Revascularization strategies were slightly different between groups; the RV-arterial uncoupling group had a lower rate of complete revascularization (37.0% [37/100] vs . 52.7% [79/150], P <0.001) and a higher rate of no revascularization (18.0% [18/100] vs . 4.7% [7/150], P <0.001) compared to the RV-arterial coupling group. The cohort with TAPSE/PASP ≤0.43 had a significantly worse prognosis than the cohort with TAPSE/PASP >0.43. Multivariate Cox analysis showed TAPSE/PASP ≤0.43 as an independent associated factor for the primary endpoint, all-cause death, and recurrent HF hospitalization (hazard ratios [HR]: 2.21, 95% confidence interval [CI]: 1.44-3.39, P <0.001; HR: 3.32, 95% CI: 1.30-8.47, P = 0.012; and HR: 1.93, 95% CI: 1.10-3.37, P = 0.021, respectively), but not for recurrent ischemic events (HR: 1.48, 95% CI: 0.75-2.90, P = 0.257). CONCLUSION: RV-arterial uncoupling, based on TAPSE/PASP, is independently associated with adverse outcomes in acute HFpEF patients with CAD.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2023) conducted a cohort in Acute heart failure with preserved ejection fraction (HFpEF) accompanied with coronary artery disease (CAD) (n=250). Right ventricular-arterial uncoupling (TAPSE/PASP ≤0.43) vs. Right ventricular-arterial coupling (TAPSE/PASP >0.43) was evaluated on Composite of all-cause death, recurrent ischemic events, and HF hospitalizations (HR 2.21, 95% CI 1.44-3.39, p=<0.001). Right ventricular-arterial uncoupling (TAPSE/PASP ≤0.43) was independently associated with the primary composite endpoint (HR 2.21; 95% CI 1.44-3.39; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: